Saturday 17 October 2026
Export ERNA’s income statement to Excel — free account
Ernexa Therapeutics Inc.
ERNA Healthcare Biotechnology
Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023. In the quarter to June 2026, revenue fell 94.1%, EPS grew 77.7% and free cash flow fell 64.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
2.09
0.08
−3.69%
Follow ERNA
| Dec '19 | Jan '20 | Dec '20 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | 0.00 | 0.00 | — |
Piotroski F-Score |
4 | — | — | — | — | — | — | — | — | — |
P/S ratio |
0.33 | 0.34 | 13.32 | — | — | — | — | 3.68 | 6.80 | — |
Altman Z-Score |
(11.60) | — | 5.34 | — | — | — | — | (6.55) | (70.69) | — |
Altman Z″-Score (non-manufacturers) |
(30.60) | — | (7.53) | — | — | — | — | (14.84) | (163.47) | — |
P/FCF ratio |
3.93 | 3.98 | 0.00 | — | — | — | — | 0.00 | 0.00 | — |
Beneish M-Score |
(3.74) | — | — | — | — | — | — | — | (24.48) | — |
P/Operating CF |
6.71 | 6.81 | (47.19) | — | — | — | — | (2.15) | (1.12) | — |
P/B ratio |
1.30 | 1.31 | 10.09 | — | — | — | — | 4.49 | 2.33 | — |
Price to Tangible BV |
1.50 | 1.52 | 13.76 | — | — | — | — | 53.25 | 0.00 | — |
EV/Sales |
0.31 | 0.31 | 13.10 | — | — | — | — | 3.50 | 59.41 | — |
EV/EBITDA |
3.10 | 3.15 | 0.00 | — | — | — | — | 0.00 | 0.00 | — |
EV/Operating CF |
2.22 | 2.26 | (9.38) | — | — | — | — | (0.47) | (2.18) | — |
EV/FCF |
3.63 | 3.69 | (9.33) | — | — | — | — | (0.47) | (2.13) | — |
Quick Ratio |
0.73 | 0.00 | 0.56 | 4.81 | 4.81 | 1.62 | 1.62 | 1.22 | 0.74 | 0.64 |
Current Ratio |
1.00 | 0.55 | 0.55 | 5.10 | 5.10 | 1.79 | 1.79 | 1.46 | 0.80 | 1.01 |
Net Debt/EBITDA |
(0.25) | (0.18) | 0.18 | 0.00 | 0.15 | 0.00 | 0.35 | 0.04 | 0.20 | 0.21 |
Debt/Assets |
19.53% | 21.04% | 2.40% | 0.00% | 0.00% | 0.00% | 0.00% | 13.79% | 0.00% | 0.00% |
Debt/Equity |
0.54 | (0.25) | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 3.03 | 0.00 | 0.00 |
Asset Turnover |
1.37 | 0.42 | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
Operating CF/Net income |
(1.33) | 0.31 | 1.11 | 0.19 | 0.19 | 0.85 | 0.85 | 0.94 | 0.36 | 0.50 |
Capex/Depreciation |
(0.29) | 0.00 | (0.40) | 0.00 | (0.34) | 0.00 | (0.09) | (0.01) | (0.05) | (0.14) |
Interest Coverage |
(7.08) | — | (52.52) | — | — | — | (1,107.23) | (34.42) | (2.32) | (345.15) |
| (34.37%) | 0.00% | (114.38%) | 0.00% | (739.19%) | 0.00% | (130.80%) | (302.47%) | (2,266.28%) | (687.80%) | |
| (14.23%) | 0.00% | (53.95%) | 0.00% | (551.69%) | 0.00% | (91.42%) | (60.73%) | (163.80%) | (253.99%) | |
ROIC |
(23.99%) | 0.00% | (71.46%) | 0.00% | (834.50%) | 0.00% | (3,140.79%) | (923.09%) | 0.00% | (1,126.57%) |
Return on Tangible Assets |
(73.76%) | (2,050.31%) | 912.52% | (668.78%) | (777.72%) | (337.24%) | (392.70%) | (616.20%) | 8,893.21% | (12,368.42%) |
Average Days of Receivables |
22.02 | 7.30 | 7.30 | 0.00 | 0.00 | 0.00 | 0.00 | 2,281.25 | 274.06 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 68.12% | 0.00% | 0.00% | 0.00% | 0.00% | 8,705.88% | 791.07% | 0.00% |
Selling, General and Administrative Expense of Revenue |
66.52% | 0.00% | 56.84% | 0.00% | 0.00% | 0.00% | 0.00% | 21,451.47% | 2,256.36% | 0.00% |
Intangible Assets out of Total Assets |
0.05 | 0.65 | 0.16 | 0.25 | 0.06 | 0.09 | 0.09 | 0.04 | 0.39 | 0.35 |
Share Based Compensation of Revenue |
1.04% | 0.00% | 1.57% | — | 0.00% | — | 0.00% | 1,826.47% | 261.17% | 0.00% |
Graham Net Nets |
(0.45) | (0.44) | (0.05) | — | — | — | — | (3.73) | (0.31) | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — | — | 0.00 | 0.00 | — |
Earnings Yield |
(32.26%) | (31.82%) | (9.25%) | — | — | — | — | (216.91%) | (1,126.63%) | — |
Free Cash Flow Yield |
25.44% | 25.10% | (10.53%) | — | — | — | — | (204.06%) | (409.27%) | — |
Revenue per Share |
99,030.00 | 0.00 | 2,521.74 | 0.00 | 0.00 | 0.00 | 0.00 | 4.79 | 15.99 | 0.00 |
Operating CF per Share |
13,720.00 | (18.42) | (3,522.17) | (10.85) | (4,049.66) | (6.88) | (2,589.63) | (1,437.18) | (435.05) | (27.81) |
Capex per Share |
(5,325.00) | 0.00 | (16.96) | 0.00 | (26.55) | 0.00 | (5.80) | (1.34) | (10.03) | (0.15) |
Free Cash Flow per Share |
8,395.00 | (18.42) | (3,539.13) | (10.85) | (4,076.21) | (6.88) | (2,595.43) | (1,438.52) | (445.08) | (27.96) |
Cash per Share |
16,295.00 | 3.71 | 708.70 | 7.85 | 2,928.45 | 3.75 | 1,413.09 | 533.45 | 47.50 | 7.47 |
Shareholders Equity per Share |
25,455.00 | (26.34) | 3,330.00 | 11.78 | 4,397.07 | 3.97 | 1,494.69 | 157.25 | 46.73 | 9.52 |
Interest Debt per Share |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
25,455.00 | (26.34) | 3,330.00 | 11.78 | 4,397.07 | 3.97 | 1,494.69 | 157.25 | 46.73 | 9.52 |
Free Cash Flow |
1.68 | (8.10) | (8.14) | (23.49) | (23.64) | (20.98) | (21.02) | (20.43) | (16.20) | (7.05) |
Working Capital |
(0.02) | (1.39) | (1.39) | 15.09 | 15.09 | 6.03 | 6.03 | 3.03 | (0.59) | 0.02 |
Capital Expenditures |
(1.06) | (0.04) | (0.04) | (0.15) | (0.15) | (0.30) | (0.05) | (0.02) | (0.36) | (0.04) |
Net Current Asset Value |
(2.96) | (23.62) | (3.51) | 12.74 | 12.74 | 3.51 | 3.51 | (37.30) | (1.22) | (0.30) |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | — | — | — | 0.00 | 0.00 | — |
Capex to Sales |
0.05 | 0.00 | 0.01 | — | 0.00 | — | 0.00 | 0.28 | 0.63 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.32 | 0.04 | 0.17 | 0.14 | 0.69 | 0.39 | 2.11 | 2.89 | 81.14 | 2.80 |
Cash ROIC |
15.11% | 114.86% | (84.80%) | 0.00% | (55.64%) | 0.00% | (89.26%) | (123.20%) | (472.33%) | (164.62%) |
Accounts Receivable Turnover |
16.94 | 8.85 | 50.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 1.35 | 0.00 |
Accounts Payable Turnover |
13.53 | 0.09 | 2.76 | 0.30 | 0.00 | 0.29 | 0.00 | 0.18 | 0.07 | 0.00 |
Inventory Turnover |
0.00 | 0.11 | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | — |
Average Days of Payables |
40.73 | 0.00 | 160.09 | 0.00 | 0.00 | 0.00 | 0.00 | 1,650.23 | 6,543.39 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | — |
Average Receivables |
1.17 | 0.66 | 0.12 | 0.40 | 0.40 | 0.82 | 0.82 | 0.69 | 0.43 | 0.27 |
Average Payables |
0.55 | 1.06 | 1.06 | 1.52 | 1.52 | 1.69 | 1.69 | 1.34 | 1.39 | 1.42 |
Average Inventory |
— | 0.87 | — | — | — | — | — | — | — | — |
Average Assets |
14.49 | 13.95 | 13.52 | 22.22 | 22.22 | 26.90 | 26.90 | 35.71 | 27.20 | 5.55 |
Average Common Equity |
6.00 | (3.25) | 6.37 | 16.58 | 16.58 | 18.80 | 18.80 | 7.17 | 1.97 | 2.05 |
Columns are period end dates